Jun6504 is an enterovirus 2C inhibitor. Jun6504 shows potent and broad-spectrum antiviral activity against multiple strains of EV-D68 (EC50 = 250 nM), EV-A71 (EC50 = 502.4 nM), and CVB3 (EC50 = 1049 nM). Jun6504 improves paralysis score and weight gain in a neonatal mouse model of EV-D68 infection. Jun6504 reduces viral titers in the spinal cord and the infected quadriceps muscle. Jun6504 can be used for EV-D68 antiviral research.

Jun15799 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 0.8, 21.1 and 3.0 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15799 has a significant antiviral activity against EV-D68 US/MO/14-18947, EV-A71 Tainan/4643/1998 and CVB3 Nancy cells (EC50s of 0.3, 11.4 and 0.3 μM, respectively). Jun15799 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis.

Jun15716 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 15.9, 44.2 and 17.8 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15716 has a potent antiviral activity against EV-D68 US/MO/14-18947 and CVB3 Nancy cells (EC50s of 1.0 and 0.7 μM, respectively). Jun15716 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis.

MDL-860 is a broad-spectrum antipicornavirus compound that has low cytotoxicity toward human cells. MDL-860 can be used for the research of virus infection.

HR-568 exhibits broad-spectrum anti-enterovirus activity. HR-568 inhibits enterovirus species EV-A71, E30 and CVA24 in cell MRC-5 with EC50 of 1.53 μM, 0.4 μM and 1.22 μM. HR-568 targets hydrophobic canyon pocket on the enterovirus capsid protein, and inhibits the virus replication.

DC07090 is a potent, reversible and competitive non-peptidyl human enterovirus 71 3C protease inhibitor with an IC50 and a Ki value for 21.72 μM and 23.29 μM. DC07090 could also inhibit coxsackievirus A16 (CVA16) replication with an EC50 value of 27.76 μM.

ZHSI-1 hydrochloride is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

ZHSI-1 is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM.

SJW-2C-227 is a broad-spectrum anti-viral compound that target enterovirus 2C potein, inhibits 2C ATPase activity, exhibits anti-viral activity of SJW-2C-227 with an EC50 of 1.7 µM against EVA71 and 0.52 µM against EV-D68.

AG-7404 (AG7404) is a potent, irreversible inhibitor of picornaviral 3C protease, exhibits EC50 values of 80-674 nM against a large panel of programmatically important poliovirus strains.

cis-Resveratrol exhibits signifcant antiviral activity. cis-Resveratrol inhibits enteroviruses with IC50s of 12.2 µM and 37.6 µM for coxsackievirus B3 (CVB3) and enterovirus 71 (EV71), respectively.

T-00127-HEV1 is a novel potent phosphoinositide kinases (PIK) inhibitor,T-00127-HEV1 inhibited PI4KB activity with a higher specificity for than other PI kinases.

DMA-135 (DMA135) is a RNA-biased small molecule binds to the EV71 SLII IRES domain (Kd=520 nM), dose-dependently (IC50=7.54 uM) inhibits EV-71 viral translation and replication.DMA-135 inhibits EV71 replication by attenuating IRES-dependent translation at dosages of relatively low cellular toxicity.DMA-135 changes the local and global structure of the EV71 SLII IRES domain.DMA-135 allosterically stabilizes a AUF1 (cellular protein)-SLII-(DMA-135) ternary complex.

DMA-135 (DMA135) is a RNA-biased small molecule binds to the EV71 SLII IRES domain (Kd=520 nM), dose-dependently (IC50=7.54 uM) inhibits EV-71 viral translation and replication.DMA-135 inhibits EV71 replication by attenuating IRES-dependent translation at dosages of relatively low cellular toxicity.DMA-135 changes the local and global structure of the EV71 SLII IRES domain.DMA-135 allosterically stabilizes a AUF1 (cellular protein)-SLII-(DMA-135) ternary complex.

EV-A71-IN-1 is a human enterovirus A71 (EV-A71) capsid protein inhibitor with an EC50 of 0.27 μM against EV-A71. EV-A71-IN-1 is a capsid binder that blocks the interaction between the viral VP1 and the host receptor hSCARB2. EV-A71-IN-1 inhibits a series of different human enteroviruses without significant cytotoxicity (CC50>56.2 μM).

DMA-135 hydrochloride inhibits enterovirus 71 (EV71) IRES-dependent translation and replication. DMA-135 hydrochloride binds to enterovirus 71 (EV71) SLII domain with moderately high affinity (KD= 520 nM). DMA-135 hydrochloride has no significant toxicity in cell-based studies.

WIN 54954 is a broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections.

(Rac)-Golgicide A ((Rac)-GCA) is a racemate of Golgicide A. Golgicide A (GCA) is a potent, highly specific, and reversible inhibitor of the cis-Golgi ADP-ribosylation factor guanine nucleotide exchange factors (ArfGEF) GBF1.Golgicide A drastically reduced replication of coxsackievirus B3 (CVB3) and other human enterovirus species.

DC07090 dihydrochloride is a low toxicity, potent, reversible and competitive non-peptidyl human enterovirus 71 3C protease inhibitor with an IC50 and a Ki value for 21.72 μM and 23.29 μM. DC07090 dihydrochloride could also inhibit coxsackievirus A16 (CVA16) replication with an EC50 value of 27.76 μM.

Golgicide A-2 (GCA-2), a Golgicide A (GCA) derivative, is the most active enantiomer of GCA. Golgicide A-2 displays high selectivity and efficiency in killing An. stephensi larvae and can be used for the research of dengue virus spread.

Vapendavir diphosphate (BTA798 diphosphate) is a potent enteroviral capsid binder (CB). Vapendavir diphosphate (BTA798 diphosphate) possesses potent antiviral activity for enterovirus 71 (EV71) replication, with EC50 values of 0.5-1.4 μM in different EV71 strains.